NEW YORK, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

文章核心观点 - 根据投诉,被告向投资者提供了有关爱德华兹预期2024财年收入的重大信息,特别是与公司核心产品经导管主动脉瓣膜置换(TAVR)业务的增长有关 [1] - 2024年7月24日,爱德华兹公布了2024财年第二季度低于预期的财务业绩,并大幅下调了TAVR业务全年收入指引 [1] - 公司将TAVR业务增长放缓归因于"结构性心脏治疗的持续增长和扩张...给医院工作流程带来压力",投资者理解这意味着新治疗方法(包括公司自身的经导管二尖瓣和三尖瓣治疗(TMTT))对医院结构性心脏团队造成了重大压力,以致于他们未充分利用TAVR,尽管公司继续声称存在大量未得到治疗的患者群体 [1] - 此外,公司在第二季度宣布了三项收购,旨在增强其替代TAVR的治疗方案,这表明公司意识到TAVR平台增长放缓的潜在风险 [1] 公司相关 - 公司名称:爱德华兹生命科学公司(Edwards Lifesciences Corporation) [1] - 股票代码:EW(纽约证券交易所) [1] - 公司主要从事经导管主动脉瓣膜置换(TAVR)业务,以及经导管二尖瓣和三尖瓣治疗(TMTT)等新兴治疗方法 [1] 财务数据 - 2024年第二季度财务业绩低于预期 [1] - 公司大幅下调了TAVR业务全年收入指引 [1] - 2024年7月24日,公司股价从收盘价86.95美元下跌至59.70美元,跌幅约31.34% [1] 投资者反应 - 投资者和分析师立即对爱德华兹的披露做出反应,公司股价大幅下跌 [1]

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/edwards-lifescie ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109666&from=3 CLASS PERIO ...

RADNOR, Pa., Oct. 29, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Edw ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/edwards-lifesciences-l ...

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 6, 2024 – July 24, 2024Lead Plaintiff Deadline: Dec. 13, 2024 Visit: www.hbsslaw.com/investor-fraud/ew Contact the Firm Now: EW@hbsslaw.com 844-916-0895 Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences’ disclosures about its ...

Have you evaluated the performance of Edwards Lifesciences' (EW) international operations during the quarter that concluded in September 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gr ...